Independent prognostic value of KRAS mutation in resected colorectal cancer based on multi-gene sequencing

Table 6 Association between genetic mutations, clinicopathological features and prognosis (5-year survival), n (%)

Variable	Total (n = 87)	Death (n = 51)	Survival (n = 36)	χ² value	P value
Gender				8.74	0.003
Female	24 (27.59)	8 (15.69)	16 (44.44)
Male	63 (72.41)	43 (84.31)	20 (55.56)
Age				1.99	0.159
< 60 years	20 (22.99)	9 (17.65)	11 (30.56)
≥ 60 years	67 (77.01)	42 (82.35)	25 (69.44)
KRAS mutation				12.69	< 0.001
Mutant	39 (44.83)	31 (60.78)	8 (22.22)
Wild-type	48 (55.17)	20 (39.22)	28 (77.78)
PIK3CA mutation				2.56	0.110
Mutant	12 (13.79)	4 (7.84)	8 (22.22)
Wild-type	75 (86.21)	47 (92.16)	28 (77.78)
FBXW7 mutation				1.02	0.314
Mutant	24 (27.59)	12 (23.53)	12 (33.33)
Wild-type	63 (72.41)	39 (76.47)	24 (66.67)
TP53 mutation				0.14	0.707
Mutant	56 (64.37)	32 (62.75)	24 (66.67)
Wild-type	31 (35.63)	19 (37.25)	12 (33.33)
Diabetes				2.17	0.141
Absent	71 (81.61)	39 (76.47)	32 (88.89)
Present	16 (18.39)	12 (23.53)	4 (11.11)
Hypertension				3.28	0.070
Absent	48 (55.17)	24 (47.06)	24 (66.67)
Present	39 (44.83)	27 (52.94)	12 (33.33)
Hyperlipidemia				0.60	0.438
Absent	71 (81.61)	43 (84.31)	28 (77.78)
Present	16 (18.39)	8 (15.69)	8 (22.22)
Smoking				2.04	0.153
Absent	63 (72.41)	34 (66.67)	29 (80.56)
Present	24 (27.59)	17 (33.33)	7 (19.44)
Alcohol use				12.48	< 0.001
Absent	62 (71.26)	29 (56.86)	33 (91.67)
Present	25 (28.74)	22 (43.14)	3 (8.33)
Tumor location				6.07	0.048
Left colon	21 (24.14)	13 (25.49)	8 (22.22)
Rectum	46 (52.87)	22 (43.14)	24 (66.67)
Right colon	20 (22.99)	16 (31.37)	4 (11.11)
Differentiation grade				12.79	< 0.001
Well/moderate	72 (82.76)	36 (70.59)	36 (100.00)
Poor	15 (17.24)	15 (29.41)	0 (0.00)
Lymphovascular invasion				5.09	0.024
Absent	51 (58.62)	35 (68.63)	16 (44.44)
Present	36 (41.38)	16 (31.37)	20 (55.56)
Perineural invasion				0.09	0.769
Absent	75 (86.21)	43 (84.31)	32 (88.89)
Present	12 (13.79)	8 (15.69)	4 (11.11)
Preoperative pathology				0.28	0.595
Adenocarcinoma (non-special)	82 (94.25)	47 (92.16)	35 (97.22)
Mucinous adenocarcinoma	5 (5.75)	4 (7.84)	1 (2.78)
T stage				5.17	0.023
T1 + T2	5 (5.75)	0 (0.00)	5 (13.89)
T3 + T4	82 (94.25)	51 (100.00)	31 (86.11)
N stage				17.02	< 0.001
N0	12 (13.79)	0 (0.00)	12 (33.33)
N1 + N2	75 (86.21)	51 (100.00)	24 (66.67)
M stage				2.17	0.141
M0	71 (81.61)	39 (76.47)	32 (88.89)
M1	16 (18.39)	12 (23.53)	4 (11.11)
Surgical approach				2.23	0.136
Laparoscopic	60 (68.97)	32 (62.75)	28 (77.78)
Open	27 (31.03)	19 (37.25)	8 (22.22)
Tumor number				7.95	0.005
Solitary	75 (86.21)	39 (76.47)	36 (100.00)
Multiple (≥ 2)	12 (13.79)	12 (23.53)	0 (0.00)
Maximum tumor diameter				9.31	0.002
< 5 cm	32 (36.78)	12 (23.53)	20 (55.56)
≥ 5 cm	55 (63.22)	39 (76.47)	16 (44.44)
Preoperative tumor markers				9.34	0.002
Absent	65 (74.71)	32 (62.75)	33 (91.67)
Present	22 (25.29)	19 (37.25)	3 (8.33)
Microsatellite				0.76	0.382
Microsatellite stable	81 (93.10)	49 (96.08)	32 (88.89)
Microsatellite instability	6 (6.90)	2 (3.92)	4 (11.11)